Do drugs that target mTOR generate CCN2-mediated fibrogenic side effects?
Crossref DOI link: https://doi.org/10.1007/s12079-019-00520-y
Published Online: 2019-05-22
Published Print: 2019-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Leask, Andrew http://orcid.org/0000-0003-2832-283X
Text and Data Mining valid from 2019-05-22
Version of Record valid from 2019-05-22
Article History
Received: 20 April 2019
Accepted: 30 April 2019
First Online: 22 May 2019